Advertisement
Video ThumbnailVideo Thumbnail
Updated: May 12, 2021, 04:45 PM IST

Coronavirus Update Bharat Biotechs Covaxin gets nod by SEC for phase 2 3 trials on 2 to 18 yrs

SEC gave nod to Bharat Biotech's Covaxin for phase 2 and 3 human clinical trials on 2 to 18 years.

Advertisement

SEC gave nod to Bharat Biotech's Covaxin for phase 2 and 3 human clinical trials on 2 to 18 years.

Read More
Advertisement
Advertisement
Advertisement